Oncomine Comprehensive Genomic Profiling NGS Research Assays

Diagnostic solutions for precision oncology



Precision medicine is transforming cancer care, offering more targeted and effective treatment options. With the advent of advanced technologies like next-generation sequencing (NGS), clinicians and lab professionals can now rapidly identify key genomic markers that guide therapy decisions.

 

These tools enable personalized treatments, tailored to each patient’s unique molecular profile. As the number of molecularly targeted therapies continues to grow, timely access to this information is more critical than ever.

Benefits of Oncomine Comprehensive assays

Oncomine CGP assays, based on Ion Ampliseq technology and enabled by Ion Torrent sequencing platforms, provide:

 

  • Simultaneous analysis of a broad range of relevant and emerging biomarkers in one test to help maximize insights into the underlying oncogenic drivers in a timely manner

  • Analysis of the main classes of genomic alterations, including single-nucleotide variants (SNVs), insertions and deletions (indels), copy number variations (CNVs), and fusions across pan-cancer samples

  • Assessment of genomic signatures, such as homologous recombination deficiency (HRD), tumor mutational burden (TMB), and microsatellite instability (MSI)

  • Easy, automated workflows with as little as 20–60 minutes of hands-on time* on the Genexus System and Ion GeneStudio S5 systems

  • Fast results as soon as next-day or three-day CGP results* for important insights

  • Robust, ~94% success rate based on Ion AmpliSeq technology with low sample input requirements so that more samples can be tested with informative results1

  • Complete, end-to-end workflow from one vendor that includes instruments, consumables, analysis, and support to simplify implementation into your laboratory

 

* Timing varies by number of samples, sample type, and instrument used.

 

 

Which Oncomine Comprehensive assay fits your clinical research needs?

Oncomine CGP assays offer broad molecular profiling in solid tumors.

  Oncomine Comprehensive Assay v3 Oncomine Comprehensive Assay Plus
Description Comprehensive genomic profiling from 161 genes Comprehensive genomic profiling from 517 genes plus genomic signatures (HRD, TMB, MSI)
Sample type FFPE tissue FFPE tissue
Number of genes 161 517
Alteration types SNVs, indels, CNVs, fusions SNVs, indels, CNVs, fusions
Genomic signatures − HRD, TMB, MSI
Recommended nucleic acid input amount  20 ng DNA/RNA 20–30 ng DNA, 20 ng RNA
Instrument Genexus System Genexus System
Ion GeneStudio S5 systems Ion GeneStudio S5 systems
Turnaround time* 1−3 days 1−3 days

* Timing varies by number of samples, sample type, and instrument used.

NGS systems for the Oncomine Comprehensive assays

Oncomine CGP assays can be run on the Genexus System and Ion GeneStudio S5 systems.

Ready to speak with a Thermo Fisher representative?

If you are interested in learning more about Oncomine CGP solutions for solid tumors and see a demo, please request contact from a local representative.

 

References

1. Jantus-Lewintre E, Rappa A, Ruano D et al. (2025) Multicenter in-house evaluation of an amplicon-based next-generation sequencing panel for comprehensive molecular profiling. Mol Diagn Ther 29(2):249–261. 

For Research Use Only. Not for use in diagnostic procedures.